CorTechs Labs Inc. expands NeuroQuant's US Market reach with expanded distribution agreement with Invivo Corporation.

LA JOLLA, Calif., Feb. 4, 2014 /PRNewswire/ -- CorTechs Labs is pleased to announce the renewed and expanded partnership and distribution agreement with Invivo Corporation (subsidiary of Philips Healthcare) for NeuroQuant^®, the leading software solution for volumetric brain atrophy in the US healthcare market.  As the only FDA approved solution that automatically quantifies the volumes of brain structures, NeuroQuant^® is a key part of Invivo's DynaSuite Neuro Imaging Solution.  "We're pleased to expand our relationship with Invivo.  With great expertise and presence in advanced clinical solutions for MRI, Invivo has been a terrific partner and has demonstrated exceptional growth with our NeuroQuant^® product in the US," said Guri Stark, CorTechs Labs' CEO.  "We look forward to partnering with Invivo to continue NeuroQuant^®'s growth momentum and establishing our vision to have NeuroQuant^® become the standard test for all brain disorders, including Alzheimer's disease, epilepsy and traumatic brain injury."

"CorTechs Labs is a pioneer in the area of software for the aid of brain diagnostics and has a tremendous track record of reliability and automation in clinical practices." Said Tom Tynes, Director of Strategic Business Development at Invivo.  "We look forward to continuing to offer our DynaSuite Neuro Imaging solution with NeuroQuant^®, benefitting from its innovative approach to providing the much needed quantitative brain volumetric information."

About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world.  CorTechs' flagship product, NeuroQuant^®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the only FDA cleared medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant^® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, epilepsy and traumatic brain injury.

About Invivo Corporation
Invivo Corporation is a subsidiary of Philips Healthcare and has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical solutions, and MRI-compatible interventional devices. Invivo prides itself on successfully developing and manufacturing high-value-added medical products to enhance MR image quality, improve physicians' diagnostic confidence and patients' health care experience.  For more information please visit www.invivocorp.com.

SOURCE CorTechs Labs, Inc.